# EDGAR Filing Document

**Accession Number:** 0001611746
**File Stem:** 0001213900-25-057295
**Filing Date:** 2025-6
**Character Count:** 9698
**Document Hash:** 4c4d8e68a876074b3624658a062b55ad
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-057295.hdr.sgml**: 20250624

**ACCESSION NUMBER**: 0001213900-25-057295

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20250624

**FILED AS OF DATE**: 20250624

**DATE AS OF CHANGE**: 20250624

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** SciSparc Ltd.
- **CENTRAL INDEX KEY:** 0001611746
- **STANDARD INDUSTRIAL CLASSIFICATION:** RETAIL-AUTO DEALERS & GASOLINE STATIONS [5500]
- **ORGANIZATION NAME:** 07 Trade & Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** L3
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38041
- **FILM NUMBER:** 251070040

**BUSINESS ADDRESS:**
- **STREET 1:** 20 RAUL WALLENBERG STREET, TOWER A
- **CITY:** TEL AVIV
- **STATE:** L3
- **ZIP:** 6971916
- **BUSINESS PHONE:** 972-3-6103100

**MAIL ADDRESS:**
- **STREET 1:** 20 RAUL WALLENBERG STREET, TOWER A
- **CITY:** TEL AVIV
- **STATE:** L3
- **ZIP:** 6971916

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SciSparc Ltd./ADR
- **DATE OF NAME CHANGE:** 20210129

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Therapix Biosciences Ltd.
- **DATE OF NAME CHANGE:** 20140624

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Form 6-K**

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of June 2025 (Report No. 2)

Commission file number: 001-38041

**<u>SCISPARC LTD.</u>**

(Translation of registrant's name into English)

**20 Raul Wallenberg Street, Tower A, <u>Tel Aviv 6971916 Israel</u>**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

**<u>CONTENTS</u>**

On June 24, 2025, SciSparc Ltd. (the "Company") issued a press release titled "SciSparc Announces 1-for-21 Reverse Share Split" a copy of which is furnished as Exhibit 99.1 to this Form 6-K.

This Report of Foreign Private Issuer on Form 6-K is incorporated by reference into the Company's registration statements on Form F-3 (File Nos. [333-286099](http://www.sec.gov/Archives/edgar/data/1611746/000101376225002218/ea0235372-f3_scisparc.htm), [333-275305](http://www.sec.gov/Archives/edgar/data/1611746/000121390023083494/ea187529-f3_scisparc.htm), [333-269839](http://www.sec.gov/Archives/edgar/data/1611746/000121390023012516/ea172999-f3_scisparc.htm), [333-266047](http://www.sec.gov/Archives/edgar/data/1611746/000121390022037966/ea162219-f3_scisparcltd.htm), [333-248670](http://www.sec.gov/Archives/edgar/data/1611746/000121390022022376/ea158932-posam_scisparcltd.htm) and [333-255408](http://www.sec.gov/Archives/edgar/data/1611746/000121390023018886/ea174796-posam_scisparc.htm)) and on Form S-8 (File Nos. [333-278437](http://www.sec.gov/Archives/edgar/data/1611746/000121390024028880/ea0203015-s8_scisparc.htm), [333-225773](http://www.sec.gov/Archives/edgar/data/1611746/000121390018008005/fs82018_therapixbiosciences.htm) and [333-286791](http://www.sec.gov/Archives/edgar/data/1611746/000121390025035801/ea0239224-s8_scisparc.htm)) filed with the Securities and Exchange Commission to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

**<u>EXHIBIT INDEX</u>**

---

| | |
|:---|:---|
| **ExhibitNo.** |  |
| **99.1** | [Press release issued by SciSparc Ltd., dated June 24, 2025, titled "SciSparc Announces 1-for-21 Reverse Share Split".](ea024677302ex99-1_scisparc.htm) |

---

**<u>SIGNATURES</u>**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **SciSparc Ltd.** | **SciSparc Ltd.** |
| Date: June 24, 2025 | By: | /s/ Oz Adler |
|  | Name: | Oz Adler |
|  | Title: | Chief Executive Officer and Chief Financial Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

![](ex99-1_001.jpg)

SciSparc Announces 1-for-21 Reverse Share Split

*Following the reverse share split, the Company will have approximately 534,600 outstanding shares, out of which approximately 516,727 will be publicly held*

Tel Aviv, Israel, June 24, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. ("SciSparc" or the "Company") (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that it intends to effect a one-for-twenty one (1-for-21) reverse share split (the "Reverse Share Split") of the Company's issued and outstanding ordinary shares, no par value per share (the "Ordinary Shares"), effective at the market open on July 3, 2025. The Ordinary Shares will continue to trade on the Nasdaq Capital Market under the existing trading symbol "SPRC" and will begin trading on a split-adjusted basis at the market open on July 3, 2025. The new CUSIP number for the Ordinary Shares following the Reverse Share Split will be M82618121.

The Reverse Share Split was approved by the Company's shareholders at the Company's Annual General Meeting of Shareholders held on October 23, 2024, to be effected at the board of directors' discretion within the approved parameters.

The Reverse Share Split will not result in an adjustment to the authorized share capital of the Company under the Company's amended and restated articles of association, as currently in effect (the "Articles"), which, as of the date hereof, consists of 75,000,000 Ordinary Shares.

The Reverse Share Split will affect all shareholders uniformly and will not alter any shareholder's percentage of ownership interest in the Company's Ordinary Shares, except for minor changes due to the treatment of fractional shares as described below. The number of issued and outstanding Ordinary Shares will be reduced from 11,225,751 Ordinary Shares to approximately 534,600 Ordinary Shares following the Reverse Share Split (subject to any further adjustments due to the treatment of fractional shares). In accordance with the Articles, no fractional Ordinary Shares will be issued as a result of the Reverse Share Split and all fractional Ordinary Shares shall be rounded to the nearest whole Ordinary Share, at the DTC participant level. In addition, a proportionate adjustment will be made to the per share exercise price and the number of shares issuable upon the exercise of all outstanding options and warrants entitling the holders to purchase Ordinary Shares. No fractional Ordinary Shares will be issued upon exercise of warrants or options. As to any fraction of an Ordinary Share which a holder would otherwise be entitled to purchase upon exercise, the Company will round up to the nearest whole Ordinary Share, according to the terms of the warrant or option.

Shareholders holding their shares in book-entry form, through a brokerage account, or in "street name" are not required to take any action, as the exchange will be processed automatically by their respective brokers or custodians. For questions or additional information regarding the exchange process, shareholders are encouraged to contact the Company's transfer agent, VStock Transfer, LLC with a mailing address of 18 Lafayette Place, Woodmere, New York 11598.

**About SciSparc Ltd. (Nasdaq: SPRC):**

SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc's focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive cannabidiol: SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer's disease and agitation; and SCI-210 for the treatment of autism and status epilepticus. The Company also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seeds' oil-based products on the Amazon.com Marketplace.

**Forward-Looking Statements:**

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, the Company is using forward-looking statements when discussing the anticipated effective date of the Reverse Share Split and the date that trading of the Ordinary Shares will begin on a split-adjusted basis. Since such statements deal with future events and are based on SciSparc's current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading "Risk Factors" in SciSparc's Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (the "SEC") on April 24, 2025, and in subsequent filings with the SEC. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.

Investor Contact:<br> IR@scisparc.com<br> Tel: +972-3-6167055